{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(32)"],"submitter":["Hamilton EP"],"funding":["Arvinas Estrogen Receptor, Inc.","Pfizer, Inc."],"pubmed_abstract":["Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human Phase I/II study, vepdegestrant monotherapy was well tolerated with clinical activity in pretreated patients with ER+/HER2- advanced breast cancer. The global, randomized Phase III VERITAC-2 study compares efficacy and safety of vepdegestrant versus fulvestrant in adults with ER+/HER2- advanced breast cancer after treatment with a CDK4/6 inhibitor plus endocrine therapy. Progression-free survival by blinded independent central review (primary end point) will be assessed in the intention-to-treat population and <i>ESR1</i> mutation-positive subpopulation. Secondary end points include overall su"],"journal":["Future oncology (London, England)"],"pagination":["2447-2455"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC11524203"],"repository":["biostudies-literature"],"pubmed_title":["VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer."],"pmcid":["PMC11524203"],"pubmed_authors":["Perkins Smith J","De Laurentiis M","Lu DR","Campone M","Wander SA","Anderson S","Hamilton EP","Hurvitz SA","Danso M","Iwata H","Liu Y","Ma C","Tran L"],"additional_accession":[]},"is_claimable":false,"name":"VERITAC-2: a Phase III study of vepdegestrant, a PROTAC ER degrader, versus fulvestrant in ER+/HER2- advanced breast cancer.","description":"Vepdegestrant (ARV-471) is an oral PROTAC ER degrader that binds an E3 ubiquitin ligase and ER to directly trigger ubiquitination of ER and its subsequent proteasomal degradation. In a first-in-human Phase I/II study, vepdegestrant monotherapy was well tolerated with clinical activity in pretreated patients with ER+/HER2- advanced breast cancer. The global, randomized Phase III VERITAC-2 study compares efficacy and safety of vepdegestrant versus fulvestrant in adults with ER+/HER2- advanced breast cancer after treatment with a CDK4/6 inhibitor plus endocrine therapy. Progression-free survival by blinded independent central review (primary end point) will be assessed in the intention-to-treat population and <i>ESR1</i> mutation-positive subpopulation. Secondary end points include overall su","dates":{"release":"2024-01-01T00:00:00Z","publication":"2024","modification":"2026-07-15T17:41:11.767Z","creation":"2025-04-04T00:29:51.186Z"},"accession":"S-EPMC11524203","cross_references":{"pubmed":["39072356"],"doi":["10.1080/14796694.2024.2377530"]}}